IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i11p6724-d829235.html
   My bibliography  Save this article

The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review

Author

Listed:
  • Sara Mucherino

    (CIRFF—Center of Pharmacoeconomics and Drug Utilization, Department of Pharmacy, Federico II University of Naples, 80131 Naples, Italy)

  • Manuela Casula

    (Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy
    IRCCS MultiMedica Hospital, Sesto S. Giovanni, 20099 Milan, Italy)

  • Federica Galimberti

    (IRCCS MultiMedica Hospital, Sesto S. Giovanni, 20099 Milan, Italy)

  • Ilaria Guarino

    (CIRFF—Center of Pharmacoeconomics and Drug Utilization, Department of Pharmacy, Federico II University of Naples, 80131 Naples, Italy)

  • Elena Olmastroni

    (Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy)

  • Elena Tragni

    (Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy)

  • Valentina Orlando

    (CIRFF—Center of Pharmacoeconomics and Drug Utilization, Department of Pharmacy, Federico II University of Naples, 80131 Naples, Italy)

  • Enrica Menditto

    (CIRFF—Center of Pharmacoeconomics and Drug Utilization, Department of Pharmacy, Federico II University of Naples, 80131 Naples, Italy)

  • on behalf of the EDU.RE.DRUG Group

    (Collaborators/Membership of the Group/Team Name is provided in the Acknowledgments.)

Abstract

Potentially inappropriate prescribing (PIP) is associated with an increased risk of adverse drug reactions, recognized as a determinant of adherence and increased healthcare costs. The study’s aim was to explore and compare the results of interventions to reduce PIP and its impact on avoidable healthcare costs. A systematic literature review was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement guidelines. PubMed and Embase were queried until February 2021. Inclusion criteria followed the PICO model: older patients receiving PIP; Interventions aimed at health professionals, structures, and patients; no/any intervention as a comparator; postintervention costs variations as outcomes. The search strategy produced 274 potentially relevant publications, of which 18 articles met inclusion criteria. Two subgroups were analyzed according to the study design: observational studies assessing PIP frequency and related-avoidable costs ( n = 10) and trials, including specific intervention and related outcomes in terms of postintervention effectiveness and avoided costs ( n = 8). PIP prevalence ranged from 21 to 79%. Few educational interventions carried out to reduce PIP prevalence and avoidable costs resulted in a slowly improving prescribing practice but not cost effective. Implementing cost-effective strategies for reducing PIP and clinical and economic implications is fundamental to reducing health systems’ PIP burden.

Suggested Citation

  • Sara Mucherino & Manuela Casula & Federica Galimberti & Ilaria Guarino & Elena Olmastroni & Elena Tragni & Valentina Orlando & Enrica Menditto & on behalf of the EDU.RE.DRUG Group, 2022. "The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review," IJERPH, MDPI, vol. 19(11), pages 1-19, May.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:11:p:6724-:d:829235
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/11/6724/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/11/6724/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Buetow, Stephen A. & Sibbald, Bonnie & Cantrill, Judith A. & Halliwell, Shirley, 1997. "Appropriateness in health care: Application to prescribing," Social Science & Medicine, Elsevier, vol. 45(2), pages 261-271, July.
    2. Katharina Elisabeth Fischer & Taika Koch & Karel Kostev & Tom Stargardt, 2018. "The impact of physician-level drug budgets on prescribing behavior," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 213-222, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Katharina Elisabeth Blankart & Tom Stargardt, 2020. "The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 63-82, October.
    2. Wenwei Liu & Suwei Yuan & Fengqing Wei & Jing Yang & Zhe Zhang & Changbin Zhu & Jin Ma, 2015. "Reliability and Validity of the Chinese Version Appropriateness Evaluation Protocol," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-11, August.
    3. Manuela Casula & Ilaria Ardoino & Carlotta Franchi, 2023. "Appropriateness of the Prescription and Use of Medicines: An Old Concept but More Relevant than Ever," IJERPH, MDPI, vol. 20(3), pages 1-5, February.
    4. Katharina E. Blankart & Friederike Arndt, 2020. "Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany," IJERPH, MDPI, vol. 17(11), pages 1-14, June.
    5. Mills, Mackenzie & Kanavos, Panos, 2020. "Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe," Health Policy, Elsevier, vol. 124(3), pages 239-251.
    6. Stacy‐ann Robinson, 2020. "Climate change adaptation in SIDS: A systematic review of the literature pre and post the IPCC Fifth Assessment Report," Wiley Interdisciplinary Reviews: Climate Change, John Wiley & Sons, vol. 11(4), July.
    7. Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2014. "Two-part payments for the reimbursement of investments in health technologies," Health Policy, Elsevier, vol. 115(2), pages 230-236.
    8. Loris Tramite & Rosa Caterina Marmo & Roberta Giordana & Rocco Palumbo, 2017. "I nuovi Livelli Essenziali di Assistenza (L.E.A.) tra economicit? ed appropriatezza: un?analisi sperimentale," MECOSAN, FrancoAngeli Editore, vol. 2017(101), pages 51-74.
    9. Daniel Avdic & Katharina E. Blankart, 2021. "A hard look at soft cost-control measures in healthcare organizations: Evidence from preferred drug policies in Germany," Papers 2021-07, Centre for Health Economics, Monash University.
    10. Berger, Michael & Pock, Markus & Reiss, Miriam & Röhrling, Gerald & Czypionka, Thomas, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation," LSE Research Online Documents on Economics 116928, London School of Economics and Political Science, LSE Library.
    11. Michael Berger & Markus Pock & Miriam Reiss & Gerald Röhrling & Thomas Czypionka, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms," International Journal of Health Economics and Management, Springer, vol. 23(1), pages 149-172, March.
    12. Claudio Lucifora & Antonio Russo & Daria Vigani, 2021. "Does prescribing appropriateness reduce health expenditures? Main effects and unintended outcomes," DISCE - Working Papers del Dipartimento di Economia e Finanza def103, Università Cattolica del Sacro Cuore, Dipartimenti e Istituti di Scienze Economiche (DISCE).
    13. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2012. "DRGs: the link between investment in technologies and appropriateness," Working Papers 31/2012, University of Verona, Department of Economics.
    14. Beatriz González López-Valcárcel & Anselmo López Cabañas & Antonio Cabeza Mora & José Antonio Díaz Berenguer & Vicente Ortún & Fayna Álamo Santana, 2005. "Drug utilization studies and data registries in primary care," Economics Working Papers 809, Department of Economics and Business, Universitat Pompeu Fabra.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:11:p:6724-:d:829235. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.